Clinical Trial

A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate whether the adjuvanted recombinant zoster vaccine (RZV) or the adjuvanted respiratory syncytial virus PreFusion protein 3 (RSVPreF3) vaccine can attenuate the progression of coronary plaque in adult individuals at risk for cardiovascular events.
Trial Details
NCT Number NCT07712380
Lead Sponsor GlaxoSmithKline
Conditions Cardiovascular Disease
Enrollment 450 participants
Start Date 2026-08-31
Primary Completion 2029-05-04 (estimated)
Study Completion 2029-05-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-17